Media coverage about Cancer Genetics (NASDAQ:CGIX) has been trending somewhat negative on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cancer Genetics earned a daily sentiment score of -0.05 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 48.1975745275328 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Several equities analysts recently weighed in on CGIX shares. HC Wainwright set a $6.00 target price on Cancer Genetics and gave the company a “buy” rating in a research report on Tuesday, January 16th. Maxim Group set a $6.00 price objective on Cancer Genetics and gave the company a “buy” rating in a research report on Wednesday, December 13th. Zacks Investment Research upgraded Cancer Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 29th. Finally, ValuEngine upgraded Cancer Genetics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $5.56.
Shares of Cancer Genetics (NASDAQ CGIX) traded down $0.02 during trading on Wednesday, hitting $1.73. The stock had a trading volume of 75,300 shares, compared to its average volume of 132,728. Cancer Genetics has a fifty-two week low of $1.55 and a fifty-two week high of $5.30. The stock has a market capitalization of $48.48, a P/E ratio of -1.78 and a beta of 1.14. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.18.
About Cancer Genetics
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.